Annual report pursuant to Section 13 and 15(d)

Subsequent Events - Collaboration Agreement (Details)

v3.8.0.1
Subsequent Events - Collaboration Agreement (Details) - Incyte - Collaboration Agreement - Subsequent event
$ in Millions
Jan. 08, 2018
USD ($)
shares
Subsequent Events  
Up-front consideration $ 10.0
Up-front consideration, cash 2.5
Up-front consideration, pre-paid research funding 7.5
Maximum target selection milestone payments and option exercise fees the Company is eligible to receive 54.0
Maximum development and regulatory milestone payments the Company is eligible to receive for each of the validated targets 50.0
Maximum commercial milestone payments the Company is eligible to receive for each of the validated targets if products arising from collaboration are approved $ 65.0
Period of written notice to terminate the agreement by Incyte 60 days
Period of written notice to terminate the agreement by the Company in the event the counterparty or one of its affiliates or sublicensees challenges the validity or enforceability of certain patent rights controlled by the Company 30 days
Period of written notice to terminate the agreement by either of the parties in the event of an uncured material breach of the collaboration agreement by the other party 30 days
Performance-based stock options  
Subsequent Events  
Number of shares in which the vesting was accelerated following the entry into the collaboration agreement | shares 63,793